Environmental

R&D intensity of 47.7% of revenue suggests a comparatively innovation-heavy footprint, but peers in life sciences often show similarly elevated research spending.

No direct emissions, energy, or waste disclosures were provided, limiting evidence of environmental leadership versus peers with more complete sustainability reporting.

Low leverage at 0.25x debt-to-equity and 0.15x net debt-to-EBITDA reduces balance-sheet pressure, but it does not materially differentiate environmental positioning from peers.

Gross margin of 53.1% can support investment in cleaner processes and compliance, yet it is not itself evidence of superior environmental performance versus peers.

Social

High R&D intensity indicates sustained investment in product development and scientific capability, which can support patient or customer outcomes relative to less research-focused peers.

Zero stock-based compensation to revenue suggests lower dilution-related employee alignment concerns, but it does not by itself establish stronger labor or culture practices than peers.

No workforce, safety, diversity, or community metrics were provided, so social assessment remains constrained versus peers with fuller disclosure.

Moderate capital discipline and low leverage may support operational continuity, but these financial metrics are only indirectly relevant to social resilience.

Governance

Zero stock-based compensation to revenue is a positive governance signal versus peers that rely more heavily on equity pay, reducing dilution and incentive complexity.

Low leverage at 0.25x debt-to-equity and 0.15x net debt-to-EBITDA indicates conservative capital structure management, which generally lowers governance and refinancing risk.

R&D spending at 47.7% of revenue implies strong board support for long-duration investment, but peer comparison is mixed because many biotech firms also prioritize research.

Absence of disclosed controversy, audit, or board-independence data prevents a stronger governance score, especially versus peers with more transparent governance reporting.

Overall Score

CTOR screens as a moderate ESG name versus peers because conservative leverage and low equity-compensation intensity are positives, but disclosure gaps limit stronger differentiation.

Score Driver: Limited ESG Disclosure Prevents The Company From Demonstrating Clear Peer-Leading Environmental And Social Positioning.